Introduction
Nucleobase/nucleoside analogues realize their cytotoxic effects by mimicking natural endogenous nucleosides (after phosphorylation -nucleotides) [1] [2] [3] [4] [5] .
The mechanism of action can be associated either with inhibition of enzymes or with substitution of endogenous nucleosides as substrates in nucleic acid synthesis, which leads to damage to DNA and RNA and disruption of DNA methylation [6] [7] [8] . It should be emphasized that for the realization of its pharmacodynamic effect nucleobase/nucleoside analogues need to fulfill many conditions: to achieve tumour cells in sufficient concentration (delivery), not to be destroyed (stability), to penetrate the membrane inside the tumour cells (usually through protein-carriers), to turn into their active forms (bioactivation), to interact with the molecular target (pharmacodynamic activity) [9] .
Often the process of triphosphorylation of nucleoside analogues is difficult or impossible because of the high specificity of cellular nucleoside-and nucleotidekinases.
The nucleoside-5'-monophosphates can not be used directly due to the fact that their transport into cells is extremely limited; in addition, they are rapidly destroyed to the corresponding nucleosides at the cell membrane.
These causes make the wide interest to the synthesis of pronucleotides, i.e. chemically modified nucleoside monophosphates and their analogues, which would have the ability to penetrate into the cell and turn into appropriate antimetabolites after chemical or enzymatic transformations.
Another aspect that limits the use of cytostatic drugs is that these drugs have undesirable side effects due to possible impact on the genetic machinery of the host cell.
In this regard, it is attractive to search for substances or their combinations, the use of which will lead to decrease the intoxication rates in organismes of tumor carriers (with antioxidants, in particular).
Thus, most authors point to the ability of antioxidants to improve the tolerability of chemotherapy and long-term results of treatment [10, 11] , supporters of a different point of view believe that antioxidants inhibit the antitumor effect of chemotherapy [12] . However, all these studies relate to the use of nutraceuticals with mild antioxidant action (β-carotene; vitamins A, C, E; selenium; melatonin, cysteine; b vitamins; vitamin D3; vitamin K3; glutathione, coenzyme Q10).
The aim of this work was to evaluate the influence of the led to Ara-CMP 5, whose purification was carried out by its recrystallization from water.
Synthesis of emoxipin 6 was carried out according to the method presented in [13] . Ara-CMP+Em 7 was obtained by evaporation of a solution of equimolar amounts of Ara-CMP 5 and emoxipin 6 into water. The resulting powder Ara-CMP+Em 7 was dried in a vacuum at 60°C to a constant weight.
Cultivation of PBMC
PBMCs (peripheral blood mononuclear cells) were isolated from the peripheral blood of healthy volunteers using the Ficoll-Verografin density gradient (Sigma, Germany) method and seeded in 10% FBS (HyClone, UK) RPMI-1640 media (Lonza, Belgium) in concentration 10 6 cells/ml. Percentage of lymphocytes and monocytes of total events was analysed by flow cytometry (CytoFLEX;
Beckman Coulter, USA) after 72 hours.
Proliferation assay
PBMCs were diluted in complete RPMI 1640 medium to a final concentration of 10 
Results and Discussion
As can be seen from the data presented at Fig. 1 The addition of Ara-CMP 5 and its emoxipin salt Ara-CMP+Em 7 at concentrations of 10 -6 to10 -4 M affected the viability and proliferative activity of PBMCs (Fig. 2 and 3) .
As can be seen from the data presented at Fig. 2 , both Ara- including IFNγ [16] .
We assumed that with the increase in the content of proinflammatory cytokines, the proliferation of the corresponding cytokine-synthesizing cells increases, as well as evidenced by the change in the weight of IFNγ +lymphocyte fractions. Indeed, cultivating of mononuclear cells with Ara-CMP changed the ratio of subpopulations of CD3 -IFNγ + (NK cells) and CD3 + IFNγ + (T-lymphocytes) in dose-dependent manner ( Fig. 4 and 5) .
As can be seen from the data presented at Fig. 4 , Ara-CMP 
